Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

AstraZeneca says COVID-19 vaccine 76% effective in new analysis, to seek U.S. approval

Coronavirus Mar 25, 2021 07:05AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Picture illustration of a vial labelled with the AstraZeneca coronavirus disease (COVID-19) vaccine
 
AZN
-0.70%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
-2.01%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Rocky Swift and Swati Pandey

(Reuters) - AstraZeneca (NASDAQ:AZN)'s said its COVID-19 vaccine was 76% effective in a new analysis of its U.S. trial - only a tad lower than the level in an earlier report this week criticised for using outdated data.

Interim data published on Monday had put the vaccine's efficacy rate at 79% but had not included more recent infections, leading to a highly unusual public rebuke from U.S health officials.

The small revision to the efficacy rate will go a long way to putting the vaccine back on track for gaining U.S. emergency use authorisation - which it plans to seek in the coming weeks - and help AstraZeneca in its efforts to dispel doubts about its effectiveness and side-effects, independent experts said.

AstraZeneca also reiterated that the shot, developed with Oxford University, was 100% effective against severe or critical forms of the disease. There have been eight severe cases - all among trial participants who received the placebo.

"The vaccine efficacy against severe disease, including death, puts the AZ vaccine in the same ballpark as the other vaccines," said William Schaffner, an infectious disease expert from the Vanderbilt University School of Medicine, adding that he expects the shot to gain U.S. approval.

The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile and Peru. The earlier interim data was based on 141 infections through Feb. 17.

It also said the vaccine showed 85% efficacy in adults 65 years and older, higher than the 80% rate reported on Monday.

AstraZeneca said the latest data has been presented to the independent trial oversight committee, the Data Safety Monitoring Board, and it plans to submit the analysis for peer-reviewed publication in the coming weeks.

"The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults," Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca said in a statement.

The drugmaker noted there were 14 additional possible or probable cases to be analysed so numbers in later updates of the trial results may fluctuate slightly.

The updated 76% efficacy rate compares with rates of about 95% for vaccines from Pfizer/BioNTech and Moderna (NASDAQ:MRNA) in their trial data.

Experts have noted, however, that AstraZeneca's latest data is particularly significant because it was compiled after more infectious variants of the coronavirus became prevalent.

"This appears to be a very effective vaccine with no safety concerns," said Paul Griffin, a professor at the University of Queensland.

"Hopefully, this should now give people the confidence that this vaccine is the right one to continue to use moving forward," he said, adding that he and his parents have received the vaccine.

AstraZeneca's vaccine is seen as crucial in tackling the spread of COVID-19 across the globe, not just due to limited supply of vaccines but also because it is easier and cheaper to transport than rival shots. It has been granted conditional marketing or emergency use authorisation in more than 70 countries.

The vaccine, once hailed as a milestone in the fight against the COVID-19 pandemic, has been dogged by questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing error.

Then this month, more than a dozen countries temporarily suspended giving out the vaccine after reports linked it to a rare blood clotting disorder in a very small number of people.

The European Union's drug regulator said last week the vaccine was clearly safe, but Europeans remain sceptical about its safety.

Canada on Wednesday said it was safe but added a warning to the vaccine's label about rare blood clots.

Its rollout has also been marred by production glitches and export curbs imposed by India and the European Union, threatening to slow global efforts to end the pandemic which has killed more than 2.8 million.

AstraZeneca says COVID-19 vaccine 76% effective in new analysis, to seek U.S. approval
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (4)
Gary SKY saw
Gary SKY saw Mar 25, 2021 11:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If this Vaccine is from China.. All hell break lose .. I told you so
Dugan Webb
Dugan Webb Mar 25, 2021 2:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How about Bidens kids in Cages, higher taxes, Gun confiscation, and endless wars!! woooohoooo!!! VaX em up babay! VaX em up now! its a song; sing sing along my friends!!
Michael Angelo
Michael Angelo Mar 24, 2021 10:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We are just cobayes in an experiment. Nobody knows, for certain, what is going to happen, which vaccine will result better, what are going to be the short and long term effects. They only are sure they want you to go back to consume because need your money. Failure is not an option, you choose.
Tony Coll
Tony Coll Mar 24, 2021 9:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Simply amazing how fast each one of these companies are able to get this data, that usually takes several years, so quickly and with the most amazingly nearly impossible positive results. You'd think, given the huge odds, that at least one would have failed, but nope, they're all ready to dose billions of people. No long term studies needed! Yay!
Kart Mak
Kart Mak Mar 24, 2021 9:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long term studies will come in the long term.
Tony Coll
Tony Coll Mar 24, 2021 9:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kart Mak would have been nice if the entire world population wasn't the study.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email